---
title: "百濟神州將在 2025 年實現盈利，收入增長達到 40%"
description: "百濟神州在 2025 年實現盈利，收入增長 40%"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277129584.md"
published_at: "2026-02-27T02:05:58.000Z"
---

# 百濟神州將在 2025 年實現盈利，收入增長達到 40%

> 百濟神州在 2025 年實現盈利，收入增長 40%

### Related Stocks

- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [XBI.US - 標普生物技術 ETF - SPDR](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [ARKG.US - 基因改革 ETF - ARK](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [ONC.US - 百濟神州](https://longbridge.com/zh-HK/quote/ONC.US.md)
- [XLV.US - 醫療業 ETF - SPDR](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [688235.CN - 百濟神州-U](https://longbridge.com/zh-HK/quote/688235.CN.md)
- [IBB.US - 納斯達克生物科技指數 ETF - iShares Nasdaq](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [PBE.US - 動態生物技術與基因組 ETF - Invesco](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [BBH.US - 生物科技 ETF - VanEck Vectors](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [BGNE.US - 百濟神州](https://longbridge.com/zh-HK/quote/BGNE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Merck Says Welireg Plus Lenvima Reduces Risk Of Disease Progression By 30% | Feb 28 (Reuters) - Merck & Co Inc:WELIREG® (BELZUTIFAN) PLUS LENVIMA® (LENVATINIB) REDUCED THE RISK OF DISEASE PROGRESSI | [Link](https://longbridge.com/zh-HK/news/277313350.md) |
| Protara falls after mid-stage trial data for lead asset in bladder cancer | Protara Therapeutics (TARA) shares fell approximately 22% following the release of interim data from a mid-stage trial f | [Link](https://longbridge.com/zh-HK/news/276778182.md) |
| Merck Divides Human Health Business Into Separate Oncology, Infectious Diseases Units | Merck Divides Human Health Business Into Separate Oncology, Infectious Diseases Units | [Link](https://longbridge.com/zh-HK/news/276600243.md) |
| Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 | Immuneering (NASDAQ: IMRX) CEO Ben Zeskind announced at Oppenheimer’s Healthcare Conference that the company is focused  | [Link](https://longbridge.com/zh-HK/news/277280010.md) |
| Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference | Alumis (NASDAQ:ALMS) executives presented Phase 3 psoriasis results for envudeucitinib at the Oppenheimer Healthcare Con | [Link](https://longbridge.com/zh-HK/news/277123919.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。